Medical Devices

Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Wednesday, May 1, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Bio-Rad Laboratories, Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern Time (11:05 AM Pacific Time).

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, May 1, 2024
Optical, Health, Surgery, Medical Devices, Employment

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock.

Key Points: 
  • LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock.
  • The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company.
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant.

Enable Me Cites New Research by Siemens Healthineers Concluding Job-Related Physical Stresses and Strains for Radiologists Are Resulting in More Turnover and Fewer Entering the Profession

Retrieved on: 
Wednesday, May 1, 2024
Health, Medical Devices, Health Technology, General Health, Radiology, Research, Science, Elbow, Siemens Healthineers, Female, Shoulder, Human musculoskeletal system, Patient, Wrist, Human, Peter Hancock (professor), Breast cancer, Nursing

Enable Me , a VELA Medical company, today cited major new research by Siemens Healthineers entitled, “The future of Mammography: 4 critical challenges,” which cites poor workplace ergonomics and physical stress and strains as among the chief reasons for high radiologist turnover and fewer graduates entering the profession.

Key Points: 
  • Enable Me , a VELA Medical company, today cited major new research by Siemens Healthineers entitled, “The future of Mammography: 4 critical challenges,” which cites poor workplace ergonomics and physical stress and strains as among the chief reasons for high radiologist turnover and fewer graduates entering the profession.
  • “And because the patient is safely seated and stable, image accuracy can be improved.”
    The Siemens researchers, based in Germany, wrote that turnover in the radiology profession is estimated at 17.5% annually.
  • “Administrators must confront the scarcity of qualified personnel alongside the growing demand for breast cancer screening services.
  • The study reported that repetitive movements adopted by the mammographer have been associated with work-related musculoskeletal disorders, resulting in long-term sickness.

Paralympic Gold Medalist Creates Custom Prosthetics for Athletes through Protolabs' Digital Manufacturing Service

Retrieved on: 
Wednesday, May 1, 2024
Manufacturing, Women, Other Health, Men, Medical Devices, Consumer, Other Sports, Physical Therapy, Olympics, General Sports, General Health, Biotechnology, People with Disabilities, Sports, Other Manufacturing, Health, Engineering, Chemicals, Plastics, Leg, Paralympic Games, Amputation, CNC, Winter Paralympic Games, Foot, Gold, Athlete, Silver, Sports equipment

This is just one of the many ways Protolabs positively impacts the world through its unique, hybrid digital manufacturing model that combines its own digital factories with a network of global manufacturing partners.

Key Points: 
  • This is just one of the many ways Protolabs positively impacts the world through its unique, hybrid digital manufacturing model that combines its own digital factories with a network of global manufacturing partners.
  • BioDapt founder, Mike Schultz, also known as “Monster Mike,” is a nine-time X Games Gold Medalist and a Gold and Silver Medalist from the 2018 Paralympic Winter Games.
  • Reliable, quick-turn manufacturing is extremely important to BioDapt and the elite athletes that it works with.
  • Protolabs has partnered with BioDapt and Schultz to iterate and rapidly CNC machine high-performance custom prosthetic equipment for Lambert in support of her Paralympic pursuit.

AtriCure Reports First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, May 1, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, International, Webcast, LAA, Pressure, Patient, Physician, GAAP, Growth, Video game

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced first quarter 2024 financial results.
  • On a sequential basis, worldwide revenue for the first quarter 2024 increased approximately 2.2% from the fourth quarter 2023.
  • Gross profit for the first quarter 2024 was $81.3 million compared to $69.6 million for the first quarter 2023.
  • AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, May 1, 2024 to discuss first quarter 2024 financial results.

Global Drug-Eluting Stents Strategic Research Report 2024: Market to Reach $11.7 Billion by 2030 - J&J Exit from DES Market Improves Prospects for Competitors - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 1, 2024
Medical Devices, Health, Stent, Patient, Growth, Safety, Polymer, DES, Pharmaceutical industry

The "Drug-Eluting Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Drug-Eluting Stents - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Drug-Eluting Stents estimated at US$7.8 Billion in the year 2023, is projected to reach a revised size of US$11.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030.
  • The evolution of drug-eluting stents (DES) is a significant chapter in medical technology, marked by continuous innovation and advancement.
  • A comparative analysis of DES focuses on physical parameters, aiding in the selection of the most suitable stent for individual patients.

Bausch + Lomb Announces First-Quarter 2024 Results

Retrieved on: 
Wednesday, May 1, 2024
Surgery, Medical Devices, Health, Pharmaceutical, Optical, News, Bausch, Care, Bausch & Lomb, Mar, Forecasting, Tax, Acquisition, EPS, Adjustment, Advertising, Ophthalmology, GAAP, Growth, Pharmaceutical industry

Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.

Key Points: 
  • Net loss attributable to Bausch + Lomb Corporation for the first quarter of 2024 was $167 million, as compared to $90 million for the first quarter of 2023, an unfavorable change of $77 million.
  • Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $24 million, as compared to $34 million for the first quarter of 2023, a decrease of $10 million.
  • GAAP Earnings Per Share (“EPS”) Basic and Diluted attributable to Bausch + Lomb Corporation for the first quarter of 2024 was ($0.48), as compared to ($0.26) for the first quarter of 2023.
  • Adjusted EPS attributable to Bausch + Lomb Corporation (non-GAAP)1 for the first quarter of 2024 was $0.07, as compared to $0.10 for the first quarter of 2023.

CONMED Corporation to Present at the BofA Securities Healthcare Conference

Retrieved on: 
Wednesday, May 1, 2024
Medical Supplies, Medical Devices, Health, Surgery, Health Technology, Other Health, Chairperson, Conference

CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m.

Key Points: 
  • CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m.
  • ET) on Tuesday, May 14, 2024 in Las Vegas, NV.
  • A live audio webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.conmed.com and will be available for replay following the event.

Novanta to Present at Baird's 2024 Global Consumer, Technology & Services Conference on Wednesday, June 5, 2024

Retrieved on: 
Wednesday, May 1, 2024
Other Manufacturing, Medical Supplies, Health, Medical Devices, Robotics, Health Technology, Technology, Manufacturing, Inc., Conference

Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird's 2024 Global Consumer, Technology & Services Conference on Wednesday, June 5, 2024, in New York, NY.

Key Points: 
  • Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Baird's 2024 Global Consumer, Technology & Services Conference on Wednesday, June 5, 2024, in New York, NY.

KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth

Retrieved on: 
Wednesday, May 1, 2024
Medical Devices, Health, Pharmaceutical, Health Technology, Medical Supplies, BSI, Calendar, Patient, GAAP, Growth, EPS

Novel Therapies net revenues declined by 21.3% primarily driven by a milestone completion for a collaboration agreement in the prior year period.

Key Points: 
  • Novel Therapies net revenues declined by 21.3% primarily driven by a milestone completion for a collaboration agreement in the prior year period.
  • Cash and cash equivalents were $10.8 million as of March 31, 2024, reflecting cash usage of $0.7 million in the first quarter of 2024.
  • Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
  • Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results.